Justin Stebbing

Last updated

Justin Stebbing PROFESSOR JUSTIN STEBBING BLACK AND WHITE.jpg
Justin Stebbing

Justin Stebbing is a British clinician-scientist specialising in oncology and cancer research. He is a professor of biomedical sciences at Anglia Ruskin University [1] and practices with the private sector Phoenix Hospital Group in London. [2]

Contents

Stebbing is co-Editor-in-Chief of the journal Oncogene . [3] He is also a visiting professor of cancer medicine and oncology at Imperial College London. [4]

Early life and education

Stebbing graduated from Trinity College, Oxford.[ citation needed ] After completion of junior doctor positions in Oxford, he trained on the residency programme at The Johns Hopkins Hospital in the US, returning to London to continue his career at The Royal Marsden and then St Bartholomew's Hospitals. His PhD research investigated the interplay between the immune system and cancer including the role of viruses. [5] [6] In 2007, he was appointed a senior lecturer, and then in 2009 a full professor, at Imperial College London. [7] In 2011, the National Institute for Health and Care Research awarded Stebbing its first Translational Professorship in Oncology, working on overcoming treatment resistance and targeted precision medicine approaches. [8]

Research career

Stebbing has published over 700 peer-reviewed papers [9] and has an h-index of 89 according to Google Scholar. [10]

Cancer research

Stebbing was an oncology professor at Imperial College London [11] and has gained a reputation for innovative treatments. [12]

He is co-Editor-in-Chief of the journal Oncogene . [13]

The charity Action Against Cancer was set up to support Stebbing's work. [14] [ failed verification ]

Stebbing's research in cancer has included work on the molecular biology of solid tumours. His group identified LMTK3 as an oncogene and therapeutic target in breast cancer. [15] The team characterised the network of microRNAs induced by the estrogen receptor. [16]

Stebbing has also worked on cancers caused by HIV and AIDS, including investigating immune reconstitution inflammatory syndrome in patients with Kaposi's Sarcoma. [17]

He has undertaken extensive work on biosimilars, [18] [ failed verification ] cheaper versions of expensive biologic drugs designed to democratise access to these. [19]

COVID-19

During the Covid-19 pandemic in early 2020, Stebbing used artificial intelligence to identify baricitinib as a potential drug treatment. [20] [21] He led studies that showed that the drug reduced mortality in COVID-19 hospitalised patients with pneumonia, which led to the drug being authorised by the US Food and Drug Administration in October 2020 as an Emergency Use Authorization at first in combination with remdesivir, then alone. [22] Stebbing wrote a book, Witness to COVID, 2020, describing its discovery, trials, studies and approval. [23]

Stebbing is part of a team that ran a phase 1/2 clinical trial using invariant natural killer T cells as an 'off-the-shelf' therapy in ventilated patients with acute respiratory distress syndrome (ARDS), the first time these cells have been used in the clinic. [24] [25]

Other research

Stebbing has worked on neurological therapies for patients with unmet medical needs who are treatment resistant or unresponsive to other existing medications. [26]

Clinical practice

Stebbing is a Fellow of the Royal College of Physicians, [7] the American Society for Clinical Investigation [27] and the Royal College of Pathologists. [7]

As a clinician-scientist at Imperial College London, Stebbing practiced with the Imperial College Healthcare NHS Trust at Charing Cross Hospital and Hammersmith Hospital. [7] He resigned his permanent position at Imperial in March 2022. [7]

He has also practiced privately in Harley Street. [28] Patients who experienced successful treatments in his care included Michael Parkinson and Lynda Bellingham. [11]

As of 2024, he practices with the private Phoenix Hospital Group, where he specialises in a range of solid malignancies, including difficult cases with few conventional options. [2]

Misconduct case

In 2020, Stebbing was investigated by the General Medical Council over allegations that he failed to provide adequate care to eleven patients he had cared for between 2014 and 2017. [29] [28] The case focused on whether Stebbing had prescribed inappropriate courses of treatment in patients whose cancers were too advanced to benefit from the treatment. [30]

After initially denying all complaints against him, Stebbing eventually admitted 30 of the 36 charges, [30] and was found guilty of another three by a Medical Practitioners Tribunal Service misconduct hearing. [31] A number of Stebbing's patients and their families supported him, saying his "aggressive treatments" brought hope. [30] However, he was found to have inappropriately treated patients given their poor prognosis, overstated benefits of treatment, failed to gain informed consent by not discussing the risks and benefits, and failed to maintain proper records. [28]

The GMG suspended Stebbing from the UK medical register for nine months, [31] with the disciplinary panel finding he had "breached the very core of the Hippocratic oath." [11] However, he was not struck off, after the panel considered mitigating factors and an "unprecedented number" of testimonials to his clinical competence from former patients, family members of patients, and colleagues, [11] finding it in the public interest to allow Stebbing to return to practice "as soon as possible". [31]

Other work

Stebbing has combined his medical career with investing, and he has worked with Atticus Capital, Lansdowne Partners, Vitruvian Partners and Chaired the Board of BB Healthcare Trust. [32] He is senior oncology advisor to Clinical ink, [33] chairs the ZephyrAI scientific advisory board, [34] and is on the boards of Etira [35] and Portage Biotech. [36] He is senior VP of clinical strategy and innovation [37] at Graviton Biosciences focusing on new treatments for fibrosis, inflammation and metabolism based on selective targeting of ROCK2.

Related Research Articles

Geriatric oncology is a branch of medicine that is concerned with the diagnosis and treatment of cancer in the elderly, usually defined as aged 65 and older. This fairly young but increasingly important subspecialty incorporates the special needs of the elderly into the treatment of cancer.

Karol Sikora is a British physician specialising in oncology, who has been described as a leading world authority on cancer. He was a founder and medical director of Rutherford Health, a company that provided proton therapy services, and is Director of Medical Oncology at the Bahamas Cancer Centre.

<span class="mw-page-title-main">Oncology</span> Branch of medicine dealing with, or specializing in, cancer

Oncology is a branch of medicine that deals with the study, treatment, diagnosis, and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:

<span class="mw-page-title-main">Carlo Gambacorti-Passerini</span> Italian oncologist and hematologist

Carlo Gambacorti-Passerini is an Italian oncologist and hematologist known for his contributions to cancer research.

Michael John Peckham was a British oncologist and artist. As a cancer physician he is best known for his contribution to the treatment of testicular cancer. His paintings were first exhibited in 1962 and he showed in numerous mixed and solo exhibitions.

Christopher M. Nutting is a British Professor of Clinical Oncology and medical consultant, specializing in head and neck cancers, who has helped develop Intensity-Modulated Radiotherapy (IMRT), an advanced form of Radiation therapy.

Kathleen I. Pritchard, is the head of oncology at Sunnybrook Health Sciences Centre in Toronto, Canada, specializing in breast cancer therapies, and leading the clinical trials division of the centre. She has authored numerous studies on women's health, breast cancer, hormone replacement therapy, public health, and research methodology. According to Thomson Reuters, Pritchard was one of the most cited researchers in the world in 2014 and 2015.

<span class="mw-page-title-main">Association of Cancer Physicians</span> Specialty association in the United Kingdom for medical oncologists

The Association of Cancer Physicians (ACP) is a specialty association in the United Kingdom for medical oncologists. The ACP is recognised by the Royal College of Physicians and the Department of Health, and provides training and regular meetings for members.

Professor Dame Lesley Jean Fallowfield DBE is a British cancer psychologist and a professor of psycho-oncology at the University of Sussex. The main outcomes of her research have been the establishment of assessment tools to measure quality of life in clinical trials of cancer patients and the design of educational programmes to improve oncologists' communication with their patients.

<span class="mw-page-title-main">Thomas Hutson</span> American oncologist and cancer researcher

Thomas E. Hutson is an American medical oncologist and cancer researcher based in Dallas, Texas. He is the director of Genitourinary Oncology Program and co-director of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center. He is a Professor of Medicine at the Texas A&M Health Science Center College of Medicine and serves as a chair of Genitourinary Research for US Oncology and McKesson.

Sir Alan William Craft is a British paediatric oncologist and Emeritus Professor of Child Health at Newcastle University. Craft was most notable for work as one of nine founders of the Children's Cancer Study Group, focusing his research on paediatric oncology, especially the epidemiology of bone tumours that further led to an oncology research unit which has been involved in aetiological studies and in particular the role of irradiation in the development of childhood cancer.

Christine M. Lovly is an associate professor of medicine at Vanderbilt University. Her research involves the development of novel treatment strategies for ALK positive lung cancer.

<span class="mw-page-title-main">UK Coronavirus Cancer Monitoring Project</span>

The UK Coronavirus Cancer Programme or UKCCP is one of the longest running UK pandemic research programmes to safeguard, monitor and protect individuals living with cancer from COVID-19 across the United Kingdom.

Cancer is one of the underlying diseases that increases the risk of COVID-19 developing to a serious illness.

Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

<span class="mw-page-title-main">Jayant S. Vaidya</span> British-Indian surgeon and oncologist

Jayant S. Vaidya is a British-Indian surgeon-oncologist and clinical academic who, together with Michael Baum and Jeffrey Tobias, developed the technique called targeted intra-operative radiotherapy (TARGIT). He is a professor of surgery and oncology at the University College London, London and the author of two books on breast cancer, one on tobacco eradication, and over 200 academic articles.

Nancy Lin is an American oncologist who works at the Dana-Farber Cancer Institute and is an Associate Professor of Medicine at Harvard Medical School. Her research considers new diagnostic strategies and treatment pathways for HER2 positive breast cancer.

Xavier Pivot is a French oncologist, university professor, breast cancer specialist and general director of the Strasbourg Cancer Institute.⁣⁣ He is best known for his research on treatments with trastuzumab in HER2-positive breast cancers.

<span class="mw-page-title-main">Indraneel Mittra</span>

Indraneel Mittra FRCS (England), FASc, FNA is an Indian cancer surgeon, basic research scientist, and public health researcher. He is the Dr. Ernest Borges Chair in Translational Research and Professor Emeritus in the Department of Surgical Oncology, Tata Memorial Centre (TMC) in Mumbai. He established the first dedicated multi-disciplinary Breast Unit in India – a model which has since been adopted by most centers in the country. He pioneered the discipline of clinical research in cancer in India and pursued the cause of improving cancer care in the developing world. In this context, and with an RO1 grant from the National Institutes of Health (NIH) of the United States, Mittra spearheaded one of the largest randomized trials of screening for early detection of breast and cervical cancer using low-cost technology approaches involving 150,000 women in the suburbs of Mumbai. He is the first Indian recipient of such a competitive grant from the NIH. In the field of laboratory research, he is credited with having discovered the wide-ranging biological activities of cell-free chromatin particles (cfChPs), which have critical implications for human health and disease, and how deactivating cfChPs can have many therapeutic effects. Prof. Mittra’s current research interests revolve around studying cfChPs in the context of evolution.

Maurice Slevin is a British medical oncologist specialising in the treatment of breast, ovarian and gastrointestinal cancers. He has made contributions to the field through both his clinical practise and research. He practised at St Bartholomew's Hospital and was a founding partner of Leaders in Oncology Care (LOC) on Harley Street.

References

  1. ↑ "Professor Justin Stebbing - ARU". aru.ac.uk. ARU. Retrieved 2022-11-30.
  2. 1 2 "Professor Justin Stebbing". Phoenix Hospital Group. Retrieved 2022-10-29.
  3. ↑ "About the Editors | Oncogene". www.nature.com. Retrieved 2022-10-29.
  4. ↑ "Home - Professor Justin Stebbing". www.imperial.ac.uk. Retrieved 2022-10-29.
  5. ↑ Stebbing, Justin; Gazzard, Brian; Douek, Daniel C. (2004-04-29). "Where Does HIV Live?". New England Journal of Medicine. 350 (18): 1872–1880. doi:10.1056/NEJMra032395. ISSN   0028-4793. PMID   15115833.
  6. ↑ Stebbing, J.; Bower, M. (2003). "Redirecting". The Lancet. Oncology. 4 (7): 438–445. doi:10.1016/S1470-2045(03)01142-2. PMID   12850195 . Retrieved 2024-01-07.
  7. 1 2 3 4 5 "Profile: Justin Stebbing". Imperial.
  8. ↑ "Current NIHR Research Professors". www.nihr.ac.uk. Retrieved 2024-01-07.
  9. ↑ "stebbing j - Search Results - PubMed". PubMed. Retrieved 2024-01-07.
  10. ↑ "Justin Stebbing". scholar.google.com. Retrieved 2024-01-07.
  11. 1 2 3 4 Brown, David (20 December 2021). "'Doctor God' Justin Stebbing avoids being struck off for dishonesty after patients rally in support". The Times. Retrieved 23 May 2024.
  12. ↑ Leonard, Ian (5 July 2021). "Oncologist Denies Taking on Too Many Patients Leading to Failings". Medscape UK. Retrieved 23 May 2024.
  13. ↑ "About the Editors". Oncogene.
  14. ↑ "Home | Action Against Cancer". www.aacancer.org. Retrieved 28 March 2023.
  15. ↑ Giamas, Georgios; Filipović, Aleksandra; Jacob, Jimmy; Messier, Walter; Zhang, Hua; Yang, Dongyun; Zhang, Wu; Shifa, Belul Assefa; Photiou, Andrew; Tralau-Stewart, Cathy; Castellano, Leandro; Green, Andrew R.; Coombes, R. Charles; Ellis, Ian O.; Ali, Simak; Lenz, Heinz-Josef; Stebbing, Justin (June 2011). "Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer". Nature Medicine. 17 (6): 715–719. doi:10.1038/nm.2351. PMID   21602804. S2CID   5279914.[ non-primary source needed ]
  16. ↑ Castellano, Leandro; Giamas, Georgios; Jacob, Jimmy; Coombes, R. Charles; Lucchesi, Walter; Thiruchelvam, Paul; Barton, Geraint; Jiao, Long R.; Wait, Robin; Waxman, Jonathan; Hannon, Gregory J.; Stebbing, Justin (21 August 2009). "The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response". Proceedings of the National Academy of Sciences. 106 (37): 15732–15737. Bibcode:2009PNAS..10615732C. doi: 10.1073/pnas.0906947106 . PMC   2747188 . PMID   19706389.[ non-primary source needed ]
  17. ↑ Bower, M.; Nelson, M.; Young, A.M.; Thirlwell, C.; Newsom-Davis, T.; Mandalia, S.; Dhillon, T.; Holmes, P.; Gazzard, B.G.; Stebbing, J. (1 August 2005). "Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma". Journal of Clinical Oncology. 23 (22): 5224–5228. doi: 10.1200/JCO.2005.14.597 . PMID   16051964.[ non-primary source needed ]
  18. ↑ Stebbing, Justin; Baranau, Yauheni; Baryash, Valeriy; Manikhas, Alexey; Moiseyenko, Vladimir; Dzagnidze, Giorgi; Zhavrid, Edvard; Boliukh, Dmytro; Stroyakovskii, Daniil; Pikiel, Joanna; Eniu, Alexandru; Komov, Dmitry; Morar-Bolba, Gabriela; Li, Rubi K.; Rusyn, Andriy; Lee, Sang Joon; Lee, Sung Young; Esteva, Francisco J. (2017). "CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial". The Lancet Oncology. 18 (7): 917–928. doi:10.1016/S1470-2045(17)30434-5. hdl:10044/1/52810. PMID   28592386 . Retrieved 2024-01-07.
  19. ↑ Stebbing, Justin; Baranau, Yauheni; Baryash, Valery; Moiseyenko, Vladimir; Boliukh, Dmytro; Antone, Nicoleta; Manikhas, Alexey; Chornobai, Anatolii; Park, Taehong; Baek, Eric Hyungseok; Lee, Jaeyong; Choi, Jiin; Kim, Nahyun; Ahn, Keumyoung; Lee, Sang Joon (2023). "Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial". Biodrugs. 37 (3): 433–440. doi:10.1007/s40259-023-00582-w. ISSN   1173-8804. PMC   10195725 . PMID   36881323.
  20. ↑ Richardson, Peter; Griffin, Ivan; Tucker, Catherine; Smith, Dan; Oechsle, Olly; Phelan, Anne; Rawling, Michael; Savory, Edward; Stebbing, Justin (15 February 2020). "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease". The Lancet. 395 (10223): e30–e31. doi:10.1016/S0140-6736(20)30304-4. PMC   7137985 . PMID   32032529.[ non-primary source needed ]
  21. ↑ Stebbing, Justin; Phelan, Anne; Griffin, Ivan; Tucker, Catherine; Oechsle, Olly; Smith, Dan; Richardson, Peter (2020). "COVID-19: combining antiviral and anti-inflammatory treatments". The Lancet Infectious Diseases. 20 (4): 400–402. doi:10.1016/S1473-3099(20)30132-8. PMC   7158903 . PMID   32113509.
  22. ↑ "Olumiant EUA FAQs | FDA". www.fda.gov. Retrieved 2024-02-14.
  23. ↑ Witness to Covid: 2020: The Diary of a Global Pandemic: Amazon.co.uk: Stebbing, Justin, Mukherjee, Siddhartha: 9781398112674: Books. ASIN   1398112674.
  24. ↑ Hammond, Terese C.; Purbhoo, Marco A.; Kadel, Sapana; Ritz, Jerome; Nikiforow, Sarah; Daley, Heather; Shaw, Kit; van Besien, Koen; Gomez-Arteaga, Alexandra; Stevens, Don; Ortuzar, Waldo; Michelet, Xavier; Smith, Rachel; Moskowitz, Darrian; Masakayan, Reed (2024-02-06). "A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome". Nature Communications. 15 (1): 974. Bibcode:2024NatCo..15..974H. doi:10.1038/s41467-024-44905-z. ISSN   2041-1723. PMC   10847411 . PMID   38321023.
  25. ↑ Reporters, Telegraph (2024-02-07). "New cancer drug could improve prognosis for Covid patients". The Telegraph. ISSN   0307-1235 . Retrieved 2024-02-14.
  26. ↑ Corp, Equilibre Biopharmaceuticals. "Equilibre Biopharmaceuticals Announces Positive Topline Results from Phase 2 Clinical Trial of EQU-001 (NCT05063877) for Safety, Tolerability and Preliminary Efficacy as Adjunctive Therapy for Focal Seizures in Adults with Epilepsy". www.prnewswire.com (Press release). Retrieved 2024-01-07.
  27. ↑ "The American Society for Clinical Investigation".
  28. 1 2 3 Leonard, Ian. "Leading Oncologist Guilty of Providing Inappropriate Treatment: MPTS". Medscape UK. Retrieved 2022-05-25.
  29. ↑ Dyer, Clare (2020-09-15). "Leading oncologist faces GMC allegations of inappropriate treatment of dying patients". BMJ. 370: m3594. doi:10.1136/bmj.m3594. ISSN   1756-1833. PMID   32933903.
  30. 1 2 3 Wellesley, Johnna; Tumilty, Emma (13 November 2022). ""Saviour or Sinner?" Why the case of Justin Stebbing matters". British Medical Journal.
  31. 1 2 3 Dyer, Clare (2021-12-21). "Oncologist with "cavalier attitude" to treatment is suspended for nine months after patients defend his practice". BMJ. 375: n3130. doi:10.1136/bmj.n3130. ISSN   1756-1833. PMID   34933876.
  32. ↑ "BB Healthcare Trust delivers as it comfortably beats its benchmark". Proactiveinvestors UK. 2018-02-14. Retrieved 2024-01-07.
  33. ↑ "Justin Stebbing, PhD, M.D. | Expert Advisor". Clinical ink. Retrieved 2024-01-07.
  34. ↑ "Zephyr AI Announces Formation of Scientific and Medical Advisory Board". www.businesswire.com. 2022-12-05. Retrieved 2024-01-07.
  35. ↑ "Leadership".
  36. ↑ "About us".
  37. ↑ "Our Company". gravitoncorp.com. Retrieved 2024-02-14.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.